LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the October 24, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS) securities between May 8, 2017, and August 23, 2017, inclusive (the “Class Period”). PetMed investors have until October 24, 2017 to file a lead plaintiff motion in this class action. To obtain information or participate in the class action, please visit the PetMed case page on our website at www.glancylaw.com/case/petmed-express-inc.
Investors suffering losses on their PetMed investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to email@example.com.
According to the complaint filed in this class action lawsuit, throughout the Class Period PetMed made false and/or misleading statements and/or failed to disclose that: (1) that the Company was marketing dangerous and addictive animal drugs to humans; (2) that, as such, the Company is vulnerable to potential civil or criminal liability, as well as other regulatory action; (3) that, as a result of the foregoing, Google may halt the Company’s advertising activities; and (4) that, as a result of the foregoing, Defendants’ statements about PetMed’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you purchased PetMed shares, you may move the Court no later than October 24, 2017 to request appointment as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.